Despite the success of PD1/PD-L1 inhibitors in skin cutaneous melanoma as well as mucosal melanoma, the response of anti-PD1/PD-L1 is rather limited in uveal melanoma (UM), the most frequent and deadly intraocular malignancy in adults17,19. This evidence concerns the gene CD274 and mucosal melanoma.